FAST FACTS AND CONCEPTS #143
PROGNOSTICATION IN HEART FAILURE
Gary M Reisfield MD and George R Wilson MD

Background  This Fast Fact reviews prognostication data in Heart Failure (HF). Although the Framingham Heart Study (1990-1999) showed a 5-year mortality rate of 50% for newly identified cases, providing accurate prognostic data for 6-12 month mortality in HF has been nearly impossible. Reasons cited include: 1) an unpredictable disease trajectory with high incidence (25-50%) of sudden death; 2) disparities in the application of evidence-based treatment guidelines; 3) inter-observer differences in New York Heart Association (NYHA) classification; and 4) heterogeneous study populations.

NYHA Classification  The NYHA classification remains the major gauge of disease severity. Based on data from SUPPORT, Framingham, IMPROVEMENT, and other studies, 1-year mortality estimates are:
- Class II (mild symptoms): 5-10%.
- Class III (moderate symptoms): 10-15%.
- Class IV (severe symptoms): 30-40%.

General Predictors of Shorter Prognosis:
- Cardiac hospitalization (triples 1-year mortality; nearly 1 in 10 die within 30 days of admission).
- Intolerance to neurohormonal therapy (i.e. beta-blockers or ACE-inhibitors) is associated with high 4 month mortality.
- Elevated BUN (defined by upper limit of normal) and/or creatinine ≥1.4 mg/dl (120 µmol/l).
- Systolic blood pressure <100 mm Hg and/or pulse >100 bpm (each doubles 1-year mortality).
- Decreased left ventricular ejection fraction (linearly correlated with survival at LVEF ≤45%).
- Ventricular dysrhythmias, treatment resistant.
- Anemia (each 1 g/dl reduction in hemoglobin is associated with a 16% increase in mortality).
- Hyponatremia (serum sodium ≤135-137 mEq/l).
- Cachexia or reduced functional capacity.
- Orthopnea.
- Co-morbidities: diabetes, depression, COPD, cirrhosis, cerebrovascular disease, and cancer.

Hospice Eligibility Guidelines  The National Hospice and Palliative Care Organization’s 1996 guidelines for heart disease admission criteria include: a) symptoms of recurrent HF at rest (NYHA class IV) and b) optimal treatment with ACE inhibitors, diuretics, and vasodilators (contemporary optimal treatment now includes β-blockers, aldosterone antagonists, and device therapies). The NHPCO guide indicates that an ejection fraction ≤ 20% is “helpful supplemental objective evidence,” but not required. The NHPCO guidelines also assert that each of the following further decreases survival: treatment resistant ventricular or supraventricular arrhythmias, history of cardiac arrest in any setting, history of unexplained syncope, cardiogenic brain embolism, and concomitant HIV disease.

Prognostic Models  Since publication of the NHPCO’s guidelines, several models have been developed for predicting short- and/or long-term mortality among HF patients. Two recent models purport to predict mortality among patients hospitalized with acutely decompensated HF. Fonarow et al (2005), using a model based on admission BUN (≥ 43 mg/dl), creatinine (≥ 2.75 mg/dl), and systolic BP (< 115 mmHg), identified in-hospital mortality rates ranging from about 2% (0/3 risk factors) to 20% (3/3 risk factors). Lee et al (2003), using a model based on admission physiologic variables and co-morbidities (almost all from above list of indicators) identified 30-day mortality and 1-year mortality rates ranging from <1% and <10%, respectively, for the lowest risk patients to >50% and >75%, respectively, for the highest risk patients. While both models are applicable to bedside use, neither has been applied prospectively or in independent patient samples, nor do they address HF treatments as predictive variables. More recently, Levy et al (2006) developed a 24-variable risk model using the PRAISE1 (n=1125) database and validated it on preexisting ELITE2, ValHeFT, UW, RENAISSANCE, and IN-CHF (n=9942) databases. The model purports to accurately estimate mean 1-, 2-, and 3-year survival and, importantly, dynamically incorporates clinical and laboratory variables, HF medications, and device therapies. It awaits

**Bottom Line** Meticulous application of medication and device therapies can and will continue to change HF prognosis. HF follows an unpredictable disease trajectory, one which is highly mutable by application of evidence-based therapies, yet still marked by a high incidence of sudden death. The 1996 NHPCO criteria are not accurate predictors of 6-month mortality. Several models have recently been developed to aid in determining short- and long-term mortality in HF patients. These models await independent, prospective validation in unselected ambulatory HF patients and will need periodic updating to control for continually evolving standards of HF care. At present, accurate prognostication remains problematic.

**References**

**Version History:** This *Fast Fact* was originally edited by David E Weissman MD and published in October 2005. It was updated in December 2006 to reflect the newly published ‘Seattle Heart Failure Model.’ Version copy-edited in April 2009; then revised again July 2015 by Sean Marks MD – reference #14 added and incorporated into text; orthopnea and intolerance to neurohormonal therapy added to predictors of shorter survival.

*Fast Facts and Concepts* are edited by Sean Marks MD (Medical College of Wisconsin) and associate editor Drew A Rosielle MD (University of Minnesota Medical School), with the generous support of a volunteer peer-review editorial board, and are made available online by the Palliative Care Network of Wisconsin (PCNOW); the authors of each individual *Fast Fact* are solely responsible for that *Fast Fact*’s content. The full set of *Fast Facts* are available at Palliative Care Network of Wisconsin with contact information, and how to reference *Fast Facts.*

**Copyright:** All *Fast Facts and Concepts* are published under a Creative Commons Attribution-NonCommercial 4.0 International Copyright (http://creativecommons.org/licenses/by-nc/4.0/). *Fast Facts*
can only be copied and distributed for non-commercial, educational purposes. If you adapt or distribute a Fast Fact, let us know!

**Disclaimer:** Fast Facts and Concepts provide educational information for health care professionals. This information is not medical advice. Fast Facts are not continually updated, and new safety information may emerge after a Fast Fact is published. Health care providers should always exercise their own independent clinical judgment and consult other relevant and up-to-date experts and resources. Some Fast Facts cite the use of a product in a dosage, for an indication, or in a manner other than that recommended in the product labeling. Accordingly, the official prescribing information should be consulted before any such product is used.